Loading...

OptiNose

DB:0OP
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0OP
DB
$388M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • OptiNose has significant price volatility in the past 3 months.
0OP Share Price and Events
7 Day Returns
8.4%
DB:0OP
2%
DE Pharmaceuticals
2.1%
DE Market
1 Year Returns
-45%
DB:0OP
-11%
DE Pharmaceuticals
-7.6%
DE Market
0OP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OptiNose (0OP) 8.4% 26.6% 54% -45% - -
DE Pharmaceuticals 2% 2.4% 9.6% -11% -13.8% 17.7%
DE Market 2.1% 3.6% 8.1% -7.6% 9.8% 12.4%
1 Year Return vs Industry and Market
  • 0OP underperformed the Pharmaceuticals industry which returned -11% over the past year.
  • 0OP underperformed the Market in Germany which returned -7.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is OptiNose undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OptiNose to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OptiNose.

DB:0OP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0OP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.74
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.736 (1 + (1- 21%) (18.67%))
0.896
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.896 * 5.96%)
5.57%

Discounted Cash Flow Calculation for DB:0OP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OptiNose is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0OP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.57%)
2019 -123.40 Analyst x1 -116.89
2020 -75.35 Analyst x2 -67.61
2021 0.40 Analyst x2 0.34
2022 80.20 Analyst x2 64.57
2023 135.35 Analyst x2 103.22
2024 183.96 Est @ 35.91% 132.89
2025 230.33 Est @ 25.21% 157.61
2026 271.13 Est @ 17.71% 175.74
2027 304.93 Est @ 12.47% 187.23
2028 331.75 Est @ 8.8% 192.95
Present value of next 10 years cash flows $830.05
DB:0OP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $331.75 × (1 + 0.23%) ÷ (5.57% – 0.23%)
$6,225.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,225.47 ÷ (1 + 5.57%)10
$3,620.81
DB:0OP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $830.05 + $3,620.81
$4,450.86
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,450.86 / 41.26
$107.86
DB:0OP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0OP represents 0.86398x of NasdaqGS:OPTN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86398x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 107.86 x 0.86398
€93.19
Value per share (EUR) From above. €93.19
Current discount Discount to share price of €8.13
= -1 x (€8.13 - €93.19) / €93.19
91.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price OptiNose is available for.
Intrinsic value
>50%
Share price is €8.13 vs Future cash flow value of €93.19
Current Discount Checks
For OptiNose to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • OptiNose's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • OptiNose's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OptiNose's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OptiNose's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0OP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.68
NasdaqGS:OPTN Share Price ** NasdaqGS (2019-03-20) in USD $9.41
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.93x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.91x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OptiNose.

DB:0OP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OPTN Share Price ÷ EPS (both in USD)

= 9.41 ÷ -2.68

-3.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptiNose is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • OptiNose is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OptiNose's expected growth come at a high price?
Raw Data
DB:0OP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
65.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.86x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OptiNose, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OptiNose's assets?
Raw Data
DB:0OP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.88
NasdaqGS:OPTN Share Price * NasdaqGS (2019-03-20) in USD $9.41
Germany Pharmaceuticals Industry PB Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 2.19x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.79x
DB:0OP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OPTN Share Price ÷ Book Value per Share (both in USD)

= 9.41 ÷ 2.88

3.27x

* Primary Listing of OptiNose.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptiNose is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess OptiNose's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. OptiNose has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OptiNose expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OptiNose expected to grow at an attractive rate?
  • OptiNose's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • OptiNose's earnings growth is expected to exceed the Germany market average.
  • OptiNose's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0OP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0OP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 65.3%
DB:0OP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 47.6%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.3%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0OP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0OP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 371 90 150 4
2022-12-31 279 40 79 4
2021-12-31 171 -18 -4 5
2020-12-31 87 -76 -78 5
2019-12-31 36 -115 -119 5
DB:0OP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -92 -107
2018-09-30 4 -85 -101
2018-06-30 2 -70 -93
2018-03-31 1 -51 -81
2017-12-31 -36 -62
2017-09-30 0 -28 -43
2017-06-30 0 -24 -35
2017-03-31 24 -2 -12
2016-12-31 48 22 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OptiNose's earnings are expected to grow significantly at over 20% yearly.
  • OptiNose's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0OP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from OptiNose Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0OP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.12 4.27 1.82 3.00
2022-12-31 1.67 2.54 0.74 3.00
2021-12-31 -0.09 0.26 -0.56 3.00
2020-12-31 -1.82 -1.77 -1.91 3.00
2019-12-31 -2.87 -2.80 -3.01 3.00
DB:0OP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.68
2018-09-30 -2.69
2018-06-30 -3.30
2018-03-31 -4.16
2017-12-31 -5.63
2017-09-30 -10.62
2017-06-30 -8.71
2017-03-31 -3.06
2016-12-31 0.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OptiNose will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OptiNose's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OptiNose has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OptiNose performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OptiNose's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OptiNose does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare OptiNose's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OptiNose's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
OptiNose's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OptiNose Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0OP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.07 -106.66 95.62 10.10
2018-09-30 4.04 -100.55 90.44 7.95
2018-06-30 2.14 -92.61 74.91 11.60
2018-03-31 0.87 -80.87 56.64 14.30
2017-12-31 -61.97 31.70 16.83
2017-09-30 0.00 -43.20 15.03 18.69
2017-06-30 0.00 -35.39 10.23 15.92
2017-03-31 23.75 -12.41 8.29 15.35
2016-12-31 47.50 1.62 6.87 15.31
2015-12-31 0.09 -40.38 6.01 22.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OptiNose has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OptiNose has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OptiNose improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OptiNose's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OptiNose has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OptiNose's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OptiNose's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OptiNose is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OptiNose's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OptiNose's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OptiNose Company Filings, last reported 2 months ago.

DB:0OP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 118.61 72.50 200.99
2018-09-30 142.73 72.32 221.49
2018-06-30 164.33 72.14 244.99
2018-03-31 126.11 71.96 209.77
2017-12-31 154.50 71.86 234.85
2017-09-30 45.44 0.00 49.41
2017-06-30 57.74 0.00 58.89
2017-03-31 16.98 15.26 36.80
2016-12-31 16.98 15.26 36.80
2015-12-31 -6.33 14.48 15.20
  • OptiNose's level of debt (61.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if OptiNose's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OptiNose has sufficient cash runway for 2.1 years based on current free cash flow.
  • OptiNose has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 70.1% each year.
X
Financial health checks
We assess OptiNose's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OptiNose has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OptiNose's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OptiNose dividends.
If you bought €2,000 of OptiNose shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OptiNose's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OptiNose's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0OP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0OP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OptiNose has not reported any payouts.
  • Unable to verify if OptiNose's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OptiNose's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OptiNose has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OptiNose's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OptiNose afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OptiNose has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OptiNose's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Miller
COMPENSATION $3,930,028
AGE 57
TENURE AS CEO 9.2 years
CEO Bio

Mr. Peter K. Miller has been the Chief Executive Officer of OptiNose US Inc., since 2010. Mr. Miller has been the Chief Executive Officer at Optinose, Inc. since 2010. He serves as the Chief Executive Officer of OptiNose AS. He served as Vice President of Walgreens Health and Wellness, a division of Walgreen Co. from May 2007 to May 2010. He co-founded Take Care Health Systems, LLC in 2004 and served as its President and Chief Executive Officer from June 2004 to May 2007. He served as the President of Janssen Pharmaceutical Limited. During 15-year career at industry leader and innovator Johnson & Johnson, Mr. Miller led multi-billion-dollar global health care companies, as President of pharmaceutical company and as worldwide President of consumer health care company. He is recognised for his ability to quickly assess a market environment and establish a clear company vision and actionable strategies to achieve success. He is an experienced builder of multi-million-dollar and multi-billion-dollar consumer brands, including Tylenol, Motrin, Pepcid and Imodium and has demonstrated a commanding grasp of the fundamentals of consumer marketing. He is a motivating, optimistic leader with a unique, energetic style and is a master of the art of making complex issues simple. He has been a Director of OptiNose US Inc. since 2008. He has been a Director of Optinose, Inc. since 2008. He served as a Director of Take Care Health Systems, LLC. He served as an Independent Director of Actua Corporation (formerly, ICG Group, Inc.) from June 21, 2010 to Actua Corporation. Mr. Miller holds a B.S. in Economics from Trinity College and an M.B.A. from Kellogg School of Management, Northwestern University.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OptiNose management team in years:

2.2
Average Tenure
47
Average Age
  • The tenure for the OptiNose management team is about average.
Management Team

Peter Miller

TITLE
CEO & Director
COMPENSATION
$4M
AGE
57
TENURE
9.2 yrs

Ramy Mahmoud

TITLE
President & COO
COMPENSATION
$3M
AGE
53
TENURE
9.2 yrs

Keith Goldan

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
47
TENURE
2.2 yrs

Mike Marino

TITLE
Chief Legal Officer & Corporate Secretary
COMPENSATION
$2M
AGE
42
TENURE
2.2 yrs

Tom Gibbs

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
46
TENURE
2.5 yrs

Ricci Whitlow

TITLE
Vice President of Technical Operations
TENURE
1.7 yrs

Jonathan Neely

TITLE
Vice President of Investor Relations & Business Operations

John Messina

TITLE
Senior Vice President of Clinical Development & Medical Affairs
TENURE
1.4 yrs

Helena Djupesland

TITLE
Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)
Board of Directors Tenure

Average tenure and age of the OptiNose board of directors in years:

1.7
Average Tenure
58.5
Average Age
  • The average tenure for the OptiNose board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joe Scodari

TITLE
Chairman of the Board
COMPENSATION
$492K
AGE
65
TENURE
1.4 yrs

Peter Miller

TITLE
CEO & Director
COMPENSATION
$4M
AGE
57
TENURE
11.2 yrs

Sriram Venkataraman

TITLE
Director
COMPENSATION
$12K
AGE
46
TENURE
9.2 yrs

Sandra Helton

TITLE
Director
AGE
68
TENURE
1.1 yrs

Bill Doyle

TITLE
Non-Management Director
COMPENSATION
$9K
AGE
56
TENURE
9.2 yrs

Josh Tamaroff

TITLE
Non-Management Director
COMPENSATION
$10K
AGE
32
TENURE
2 yrs

Wilco Groenhuysen

TITLE
Director
COMPENSATION
$339K
AGE
60
TENURE
1.4 yrs

Robert O'Neil

TITLE
Director
AGE
68
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • OptiNose insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Mar 19 Sell Thomas Gibbs Individual 07. Mar 19 07. Mar 19 -2,000 €7.34 €-14,680
14. Dec 18 Buy Peter Miller Individual 13. Dec 18 13. Dec 18 10,000 €6.76 €67,638
12. Dec 18 Buy Joseph Scodari Individual 12. Dec 18 12. Dec 18 6,430 €6.95 €44,660
15. Aug 18 Buy Peter Miller Individual 15. Aug 18 15. Aug 18 10,752 €12.65 €136,000
15. Aug 18 Buy Thomas Gibbs Individual 15. Aug 18 15. Aug 18 2,000 €11.21 €22,418
13. Jun 18 Sell Avista Capital Holdings, L.P. Company 11. Jun 18 11. Jun 18 -2,875,000 €17.71 €-50,924,626
11. Jun 18 Buy Robert O'Neil Individual 08. Jun 18 08. Jun 18 2,000 €19.34 €38,689
X
Management checks
We assess OptiNose's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OptiNose has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

Details
Name: OptiNose, Inc.
0OP
Exchange: DB
Founded: 2010
$341,974,234
41,264,422
Website: http://www.optinose.com
Address: OptiNose, Inc.
1020 Stony Hill Road,
Suite 300,
Yardley,
Pennsylvania, 19067,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OPTN Common Stock Nasdaq Global Select US USD 13. Oct 2017
DB 0OP Common Stock Deutsche Boerse AG DE EUR 13. Oct 2017
Number of employees
Current staff
Staff numbers
104
OptiNose employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 22:34
End of day share price update: 2019/03/20 00:00
Last estimates confirmation: 2019/03/07
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.